Total revenue of Junshi Biosciences was approximately RMB1,948 million in 2024, representing an increase of approximately 30% compared to 2023, which was mainly due to the increase in revenue from ...

More than 85% of patients with small-cell lung cancer dosed with BioNTech’s investigational bispecific antibody BNT327 responded to the treatment, according to a mid-stage readout on Friday. The data, ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Resonant Soft X-ray Scattering (RSoXS) has emerged as a powerful technique for probing ...

Preliminary results from the phase 1b/2 Olvi-Vec-SCLC-202 trial show that adding olvimulogene nanivacirepvec (olvi-vec; GL-ONC1), a modified oncolytic vaccinia virus, to platinum-based chemotherapy ...